Full-Time

Principal Scientist-Infectious Disease

Posted on 7/5/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$126.7k - $206.9k/yr

Senior, Expert

Tarrytown, NY, USA

In Person

Category
Lab & Research
Life Sciences
Requirements
  • Ph.D. in immunology, infectious disease, virology or related field
  • Strong record of innovation and publication
  • 5+ years of experience
  • Proven expertise in T cell biology
  • Experience with in vitro and in vivo experiments
Responsibilities
  • Lead and manage research projects, either directly or by mentoring team members
  • Design and conduct T cell characterization experiments, such as cytotoxicity assays and cytokine activation assays
  • Collaborate on evaluating new antiviral antibody therapeutic strategies, including performing viral neutralization assays
  • Independently design, execute, and analyze in vitro and in vivo experiments
  • Present findings regularly to internal and cross-departmental teams
  • Discover and validate novel viral targets for T cell-based therapeutics
Desired Qualifications
  • Enjoy a dynamic, fast-paced environment
  • Love to learn, innovate and have a growth mindset
  • Independent and a critical problem solver
  • Resilient in overcoming challenges and expanding areas of expertise
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and strategic partnerships. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 23andMe assets boosts consumer genomics and drug discovery capabilities.
  • Dupixent's success in respiratory treatments strengthens market position.
  • Strategic partnerships integrate advanced technologies into treatment solutions.

What critics are saying

  • Integration challenges with 23andMe's consumer-focused business model.
  • Failure of AERIFY-2 study may impact investor confidence.
  • Intensifying competition in biologics market could affect Dupixent's market share.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmaData
Jun 25th, 2025
Regeneron Launches Innovative Donation Matching Initiative in Partnership with Independent Patient Assistance Charity

Regeneron launches innovative donation matching initiative in partnership with independent patient assistance charity.

PharmiWeb
Jun 16th, 2025
Eaaci: Dupixent Demonstrated Superiority Over Xolair (Omalizumab) In Chronic Rhinosinusitis With Nasal Polyps In Patients With Coexisting Asthma In First-Ever Presented Phase 4 Head-To-Head Respiratory Study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpointsDupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeksResults reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. Eugenio De Corso, MD, PhD ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates